Search Results - "Cheng, Judy WM"

Drug Therapy Recommendations from the 2005 ACC/AHA Guidelines for Treatment of Chronic Heart Failure by Howard, Patricia A, Cheng, Judy WM, Crouch, Michael A, Colucci, Vincent J, Kalus, James S, Spinler, Sarah A, Munger, Mark

“…Objective: To review and discuss key aspects of the drug therapy recommendations in the American College of Cardiology (ACC)/American Heart Association (AHA)…”
Get full text

Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age by Buckley, Leo F., Rybak, Eva, Aldemerdash, Ahmed, Cheng, Judy W.M., Fanikos, John

“…A growing number of patients with an indication for stroke prevention in atrial fibrillation have kidney‐, age‐, or weight‐related alterations in…”
Get full text

Current perspectives on the role of the pharmacist in heart failure management by Cheng, Judy Wm

“…Pharmacists play an important role within a multidisciplinary health care team in the care of patients with heart failure (HF). It has been evaluated and…”
Get full text

Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol by Sotiriou, CG, Cheng, JW

“…OBJECTIVE: To review the benefits of statins in coronary artery disease management beyond their cholesterol-lowering effects. DATA SOURCES: A MEDLINE search…”
Get full text

Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar by Cheng, Judy Wm

“…This article reviews the pharmacology, clinical efficacy, and safety of vorapaxar in reducing cardiovascular risk. Vorapaxar is a tricyclic himbacine-derived…”
Get full text

The Role of Vasopressin in the Treatment of Vasodilation in Shock States by Rozenfeld, Vitalina, Cheng, Judy WM

“…OBJECTIVE: To review the role of vasopressin in the treatment of vasodilatory shock. DATA SOURCES: A MEDLINE search on published reports (1966–April 1999) was…”
Get full text

Cardiology: Pharmacologic Management of Heart Failure with Preserved Ejection Fraction by Huang, Dana, Cheng, Judy WM

“…Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence…”
Get full text

Comparison of Ambulatory, High-Dose, Intravenous Diuretic Therapy to Standard Hospitalization and Diuretic Therapy for Treatment of Acute Decompensated Heart Failure by Buckley, Leo F., PharmD, Seoane-Vazquez, Enrique, PhD, Cheng, Judy W.M., PharmD MPH, Aldemerdash, Ahmed, PharmD, Cooper, Irene M., RN, Matta, Lina, PharmD MPH, Medina, Danika S., RN, Mehra, Mandeep R., MD, Navarro-Velez, Kristina, RN, Shea, Elaine L., RN, Weintraub, Joanne R., NP, Stevenson, Lynne W., MD, Desai, Akshay S., MD MPH

“…Abstract Innovative treatment strategies for decompensated heart failure (HF) are required to achieve cost savings and improvements in outcomes. We developed a…”
Get full text

Oral Terbutaline in Replacement for Intravenous Dopamine in a Patient with End-Stage Heart Failure by Miles, Adele, Shulan, Andrew, Cheng, Judy WM

“…OBJECTIVE To describe the replacement of intravenous dopamine with oral terbutaline in a patient with American College of Cardiology/American Heart Association…”
Get full text

A Review of the Use of Angiotensin Receptor Blockers for the Prevention of Cardiovascular Events in Patients with Essential Hypertension Without Compelling Indications by Zaiken, Kathy, Hudd, Timothy R, Cheng, Judy WM

“…OBJECTIVE To review the role of angiotensin receptor blockers (ARBs) for the prevention of cardiovascular events in patients with essential hypertension…”
Get full text

Azilsartan/chlorthalidone combination therapy for blood pressure control by Cheng, Judy Wm

“…Edarbyclor(®) is a combined angiotensin receptor blocker (ARB) and thiazide-like diuretic (azilsartan and chlorthalidone), and was approved on December 20,…”
Get full text

Vernakalant in the Management of Atrial Fibrillation by Cheng, Judy WM

“…OBJECTIVE: To review the pharmacology and clinical evidence of the use of vernakalant in the management of atrial fibrillation (AF). DATA SOURCES:…”
Get full text

Use of biological based therapy in patients with cardiovascular diseases in a university-hospital in New York City by Chagan, Larisa, Bernstein, Diane, Cheng, Judy W M, Kirschenbaum, Harold L, Rozenfeld, Vitalina, Caliendo, Gina C, Meyer, Joanne, Mehl, Bernard

“…The use of complementary and alternative products including Biological Based Therapy (BBT) has increased among patients with various medical illnesses and…”
Get full text

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events by Sylvester, Katelyn W, Cheng, Judy Wm, Mehra, Mandeep R

“…Low dose aspirin therapy plays a fundamental role in both the primary and secondary prevention of cardiovascular events. Although the evidence using low dose…”
Get full text

Management of atrial fibrillation: focus on the role of dronedarone by Cheng, Judy Wm

“…Dronedarone is an amiodarone derivative that was approved in the US in July 2009 to reduce the risk of cardiovascular hospitalization in patients with…”
Get full text

Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events by Cheng, Judy WM

“…Objective: To review published evidence on the use of nonselective, non-aspirin nonsteroidal antiinflammatory drugs (NANSAIDs) and the risks of cardiovascular…”
Get full text

Pharmacoeconomic review of medical management of persistent asthma by Cheng, Judy W M, Arnold, Renée J Goldberg

“…Asthma affects 20 million Americans and causes a substantial loss of productivity. Medications help to increase symptom-free days and improve quality of life…”
Get more information

Use of Erythropoietin in Heart Failure Management by Caiola, Krista, Cheng, Judy WM

“…OBJECTIVE To review the use of erythropoietin for anemia in heart failure (HF). DATA SOURCES Peer-reviewed articles in MEDLINE (1966–June 2004) were identified…”
Get full text

Early Experiences and Clinical Implications of Drug-Eluting Stents: Part 1 by Chong, Pang H, Cheng, Judy WM

“…OBJECTIVE To review the pathogenesis of in-stent restenosis and the evolution of drug-eluting stents (DES). DATA SOURCES Using the search terms sirolimus,…”
Get full text

The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease by Cheng, Judy W. M., Bhatt, Snehal H., Goldman-Levine, Jennifer D.

“…Diabetes increases the risk of cardiovascular diseases. While improving glycemic control has been demonstrated to reduce microvascular complications, the…”
Get full text